0.49
+4.26%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Valerio Therapeutics
Its shares trade on Euronext Paris under the ticker ALVIO.PA. It has been listed since 12 July 2005. In the fiscal year to 31 December 2025, it reported revenue of €2.6m and a net loss of €4.9m. At that date it held total assets of €15.2m and shareholders' equity of €2.1m.
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Jul 2005
- Employees
- 39
- Website
- onxeo.com ↗
Leadership
Pay as last reported
- Dr. Jacques MalletChairman of the Board
- Mr. Julien MiaraChief Executive Officer, Executive Director, since 2020
- Mr. Antoine BaroukyDeputy Chief Executive Officer, Executive Director, since 2025
- Mr. Nicolas TreboutaMember of the Board - Permanent Representative of Financiere de la Montagne€9,450
- Mr. Bryan GiraudoIndependent Member of the Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Valerio Therapeutics SA targets tumor DNA functions with unique DDR mechanisms for orphan diseases.
- Livatag is in Phase III for primary liver cancer treatment with doxorubicin Transdrag.
- Beleodaq/belinostat is registered in the US for PTCL treatment with development opportunities.
Weaknesses
- Validive is in Phase II for severe oral mucositis treatment with clonidine Lauriad.
- Loramyc/Oravig is registered in Europe and the US for oropharyngeal candidiasis treatment.
- Sitavig is registered for recurring herpes treatment in Europe and the US.
Opportunities
- Livatag's Phase III development for primary liver cancer offers significant market potential.
- Validive's Phase II stage for head and neck cancer patients presents growth opportunities.
- Beleodaq/belinostat's US registration for PTCL allows further development in oncology.
Threats
- Valerio Therapeutics SA has only 39 employees, indicating limited resources.
- The company's focus on orphan diseases may restrict market size and revenue potential.
- Two initial drugs in Europe and the US face competition in established markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.